Drugs in the Pipeline
MK-2060 is an investigational monoclonal antibody designed to inhibit the activation of Factor XI and its ability to activate downstream proteins.
Elacestrant showed a statistically significant and clinically meaningful progression-free survival improvement compared with standard of care.
Monitoring bESR1mut enabled optimization of the endocrine therapy used with a CDK4/6 inhibitor.
Study findings do not support initiation of uric acid-lowering therapy to prevent CKD.
This study raises important questions about the choice between lactated Ringer and saline.
Uncertainty regarding diuretic efficacy and optimal dosing in hemodialysis likely contributes to practice variation, according to investigators.
Affordability of SGLT2i may contribute to the low prescription rate in CKD.
Study findings highlight an "unmet need" for newer therapies.
A list of contraindications and drug interactions for HIV medications.